Merck: Erbitux Phase III Study - FLEX Increases Overall Survival In First-line Treatment Of
Merck: Erbitux Phase III Study - FLEX Increases Overall Survival In First-line Treatment Of
|
Merck KGaA announced that Erbitux® (cetuximab) combined with vinorelbine plus cisplatin met the primary endpoint of increasing overall survival compared with chemotherapy alone in a Phase III study initiated by Merck Serono in patients with advanced non-small cell lung cancer (NSCLC). [click link for full article] |
read more...
News entry number 1690 added on Sep 13, 2007 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
4. New York Methodist Hospital Set To Begin A Clinical Trial That May Help Emphysema Sufferers Breathe
Categorie:
Categorie:
Related Links
- Treatment With PEGASYS(R)/COPEGUS(TM) Provides Hope For Hepatitis C Patients Whose Infection Did Not
- The Relationship Between Anxiety And Time To Treatment For Patients With Prostate Cancer On Surveill
- Actin-Branching Protein Localization In Spines, Role For Frizzled In Neuron Survival, Horizontal
- Clavis Pharma ASA To Present Phase I Clinical Results From ELACYT In Patients With Cancers Of The Bl
- Few San Francisco Residents Enroll In Health Care Program After City Increases Income Eligibility Li
- Memory Pharmaceuticals Announces Positive Phase 2a Results For MEM 3454 In Alzheimer's Disease
- Non-Surgical, Low-Tech Treatment For Clubfoot The Focus At International Symposium
- Sleep Treatment Often Denied To Insomnia Patients When They Have Mental Health Conditions
- FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Wireless technology hits security budgets
- Google forced to push image in China
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
- Ho-hum, the guest's another candidate
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Microsoft purchase of RIM nice to consider, but unlikely
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
610
8
610